Avadel Pharmaceuticals plc
AVDL US
AVDL USAvadel Pharmaceuticals plc
United States Composite15.69
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Gregory J. Divis Jr.
- Full Time Employees
- 154
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 10 Earlsfort Terrace Dublin Ireland 2
- IPO Date
- Jun 7, 1996
- Website
- www.avadel.com
- Business
- Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Company News
Oppenheimer Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors
Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
Avadel Pharma gains during hearing over dispute on FDA approval of a sleep disorder drug
Buy Rating Affirmed for Avadel Pharmaceuticals Amidst Strong Growth Potential and Market Expansion
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q1 2024 Earnings Call Transcript
Q1 2024 Avadel Pharmaceuticals PLC Earnings Call Transcript
Analysts Offer Insights on Healthcare Companies: Definitive Healthcare Corp (DH) and Avadel Pharmaceuticals (AVDL)
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net ...
Avadel Pharmaceuticals GAAP EPS of -$0.30 misses by $0.29, revenue of $27.18M beats by $1.28M
Avadel Pharmaceuticals Reports First Quarter 2024 Earnings: Revenue Surpasses Estimates but Net Loss Widens
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8
Wall Street Analysts Predict a 28.58% Upside in Avadel (AVDL): Here's What You Should Know